Hint: Only one of these stocks is a strong buy.
News & Analysis: Gilead Sciences
The 31 petitioners also want federal agencies to tap third-party manufacturers to help boost the supply.
Both big drugmakers have the potential to make billions from their COVID-19 programs.
It's an easy answer.
There’s a lot to like about these pharma powerhouses, but one is trending better than the other.
GILD earnings call for the period ending June 30, 2020.
The company will pay the new distribution in September.
Tech Giants Send Nasdaq Up 150+, but Coronavirus Vaccine Stocks Suffer on Gilead Earnings, Moderna Hack Attack
The tech-heavy index kept leading the overall market upward.
It wasn't pretty, but look for an improvement in the second half of this year.
Their groundbreaking research on CAR T-cell therapies could revolutionize how certain cancers are treated in the future.